SEC Form 4 · accession 0001209191-19-012336

NEKTAR THERAPEUTICS · NKTR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Howard W Robin

Officer — President & CEO · Director

Period of report

Feb 19, 2019

Accepted (ET)

Feb 21, 2019 · 8:16 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000906709

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 19, 2019	M	33,333	$7.21	A	350,924	D
Common Stock^F1,F2	Feb 19, 2019	S	33,333	$42.32	D	317,591	D
Common Stock^F3,F4	Feb 19, 2019	S	8,882	$42.39	D	308,709	D
Common Stock^F1	Feb 20, 2019	M	33,334	$7.21	A	342,043	D
Common Stock^F1,F5	Feb 20, 2019	S	33,334	$43.20	D	308,709	D
Common Stock^F1	Feb 21, 2019	M	33,333	$7.21	A	342,042	D
Common Stock^F1,F6	Feb 21, 2019	S	33,333	$41.01	D	308,709	D
Common Stock	holding	—	—		—	410	I	by spouse

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock^F1	$7.21	Feb 19, 2019	M	33,333	D	Feb 8, 2016	Feb 7, 2020	Common Stock	33,333	166,667	D
Common Stock^F1	$7.21	Feb 20, 2019	M	33,334	D	Feb 8, 2016	Feb 7, 2020	Common Stock	33,334	133,333	D
Common Stock^F1	$7.21	Feb 21, 2019	M	33,333	D	Feb 8, 2016	Feb 7, 2020	Common Stock	33,333	100,000	D

Explanation of responses

F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Robin for certain options expiring on February 7, 2020.
F2This transaction was executed in multiple trades at prices ranging from $41.87 to $42.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F3Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F5This transaction was executed in multiple trades at prices ranging from $42.82 to $44.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F6This transaction was executed in multiple trades at prices ranging from $40.24 to $42.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.